GLP-1 juggernauts Eli Lilly and Novo Nordisk, whose combined $1.18 trillion market cap now exceeds Johnson & Johnson, AbbVie, and Merck combined, have staked their claim as stock market darlings. This momentum is particularly evident in Novo Nordisk’s remarkable trajectory, reaching a $604 billion market capitalization by March 2024 and securing its position as the…
R&D Market Pulse: NVIDIA hits $37.5B in revenue while UK regulators tap brakes on AI startup investment oversight
In a move signaling a more relaxed regulatory approach to the booming AI sector, UK regulators announced they would not investigate Google’s $2 billion investment in AI startup Anthropic. The move mirrors a similar decision regarding Amazon’s earlier $4 billion stake. This green light comes as Amazon doubles, bringing its total investment in Anthropic to…
Unleash Innovation with High Purity Metal Salts
By Rama Ghosh, Ph.D., Global Product Manager, MilliporeSigma High-purity salts are finding new applications in the synthesis of next-generation battery materials, supercapacitors, inorganic nanoparticles, electronic devices, and organic reactions. These salts undergo rigorous purification processes to eliminate impurities and contaminants, resulting in a products with exceptional chemical purity. MilliporeSigma offers high-purity salts, both anhydrous and…
Unlocking the potential of 3D Bioprinting – TissueFab® ready-to-use bioinks
By Elizabeth Aisenbrey, Ph.D., Global Product Manager 3D bioprinting is a powerful tool that enables researchers to create reproducible 3D constructs for high throughput screening and in vitro tissue models. The ease of use and ability to seamlessly print multi-materials make micro-extrusion-based bioprinting an attractive technique. Despite promising advancements in 3D bioprinting technology, a need…